Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a sell rating to a hold rating in a report issued on Sunday.

ATNM has been the subject of several other reports. HC Wainwright reiterated a buy rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, April 29th. Maxim Group lifted their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $25.72.

Actinium Pharmaceuticals Trading Down 0.6 %

ATNM opened at $8.79 on Friday. Actinium Pharmaceuticals has a 12-month low of $4.00 and a 12-month high of $9.86. The company has a market capitalization of $261.62 million, a P/E ratio of -5.14 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. On average, equities research analysts predict that Actinium Pharmaceuticals will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. Brandywine Global Investment Management LLC acquired a new position in Actinium Pharmaceuticals in the 3rd quarter valued at $1,033,000. Creative Financial Designs Inc. ADV grew its holdings in Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals during the 1st quarter valued at $78,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.